Oxford BioDynamics announces US launch of its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) foroncology
- Feb 19, 2025
- 2 min read
Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) for oncology
First-of-its-kind precision medicine test to predict a cancer patent's response
to an Immune Checkpoint Inhibitor (ICI)
Provides guidance to support critical treatment decisions on beginning or
continuing treatment with this essential class of cancer therapeutic
A significant advancement in harmonizing the prediction of response to ICI
treatment, as demanded by the FDA and oncologists
Clinically validated blood test now available to oncologists across the US
EpiSwitch CiRT delivers best in class performance: 93% sensitivity, 82%
specificity, 85% accuracy
Oxford, UK - 25 February 2022 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on its EpiSwitch 3D genomics platform, has announced
the successful clinical validation and US launch of its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT). The first-of-its-kind clinical blood test predicts the likelihood of a cancerpatient's response to an essential, widely used class of therapeutics - Immune Checkpoint Inhibitors (ICIs) - including anti-PD-L1 and anti-PD-1 immunotherapies. The robust EpiSwitch qPCR blood test has demonstrated best-in-class performance, with high sensitivity (93%), specificity (82%), and accuracy (85%) across several ICI's from multiple pharmaceutical companies and more than 15 key oncological indications. OBD's EpiSwitch CiRT enables doctors to make an informed decision on whether to recommend beginning or continuing treatment with an ICI. Using a routine blood test rather than an invasive biopsy, CiRT offers fast, personalized guidance. OBD has partnered with NEXT Molecular Analytics (VA, USA) to clinically validate EpiSwitch CiRT within its high complexity CLIA-certified laboratory. Delivering the CiRT as an LDT is consistent with OBD and NEXT's aim of getting these important tests into the hands of physicians to meet demand
and help patients as quickly as possible.
Tom Reynolds, President of NEXT Molecular Analytics said: "We are excited to be working with Oxford BioDynamics to bring this novel and sensitive Checkpoint Inhibitor Response test to oncologists and their patients in the US market. The EpiSwitch CiRT will provide oncologists with a powerful new tool to help manage complex treatment decisions with their patients." EpiSwitch CiRT was built using OBD's well-established EpiSwitch 3D genomics platform, used to discover the most important drivers that determine a patient's response to ICIs. For each patient, CiRT captures a personal fingerprint of their complex cancer genomic and immune system interactions. The EpiSwitch platform has been leveraged by leading pharma and clinical research teams for practical patient stratification in prognostic, predictive and early diagnostic applications across immuno-oncology, autoimmune and neurodegenerative indications. The US launch of CiRT follows the earlier launch of EpiSwitch CST (COVID Severity Test) and expands OBD's immune health test offerings. Further information about the EpiSwitch® CiRT is available at: www.myCiRT.com.
J’ai récemment passé plusieurs semaines à comparer des offres immobilières dans le nord du Maroc et j’ai remarqué que Tanger possède une dynamique assez particulière par rapport à d’autres villes marocaines. Certains quartiers évoluent très vite tandis que d’autres gardent une ambiance plus résidentielle et stable. En consultant Immo Tanger experts, j’ai trouvé intéressant le fait que les informations semblent organisées de manière assez claire pour aider à comprendre ces différences. Cette approche paraît plus utile que beaucoup de plateformes où les annonces sont simplement empilées sans véritable contexte autour du marché local.
I recently spoke with travelers who spent several days crossing the Atlas Mountains, and they mentioned how important the organization of the trip was for enjoying the experience properly. Distances between villages can be longer than expected, and the atmosphere changes significantly from one valley to another. Looking through Sun Trails atlas tours, I got the impression that the trips are structured around a more thoughtful pace, allowing travelers to actually experience the mountain environment instead of constantly moving from stop to stop. For people interested in cultural immersion and landscapes rather than rushed sightseeing, this kind of travel style seems much more rewarding.
Avec le nombre croissant de plateformes de streaming et de services IPTV disponibles aujourd’hui, je trouve que beaucoup d’utilisateurs ont du mal à comprendre les vraies différences entre les offres. Certains services fonctionnent très bien sur Smart TV mais deviennent instables sur d’autres appareils, alors que d’autres proposent une meilleure fluidité mais moins de contenu. En consultant EnParlons abonnement IPTV, j’ai apprécié le fait que le sujet soit abordé de manière assez pratique, sans tomber dans un discours exagéré. Les informations donnent une vision plus réaliste de l’expérience utilisateur et permettent de mieux comprendre ce qu’il faut regarder avant de choisir un abonnement IPTV.